Pharma Pulse 10/30/24: The State of Compounding, Apple’s AI Success Hinges on the iPhone & more

The State of Compounding: Q&A with Olympia Pharmaceutical’s Mark Mikhael

Mark Mikhael, CEO of Olympia Therapeutics, spoke with Pharmaceutical Executive about the compounding industry, which has a renewed spotlight on it due to recent high profile drug shortages.

How Employers Are Trying To Tame Healthcare Costs

Changing the site of care to less expensive locations. and putting biosimilars are favored strategies, according to a survey conducted by the National Alliance of Healthcare Purchaser Coalitions

Why Apple’s AI Success Hinges on the iPhone

Big tech rivals can distribute AI widely through their services, while Apple’s hardware-centric business needs its devices as the touchpoint.

GoodRx Announces Exclusive Low Cash Price for QSYMIA®

GoodRx announced that QSYMIA® (phentermine and topiramate extended-release capsules CIV) is available for a low cash price in more than 70,000 retail pharmacy locations nationwide exclusively via GoodRx. This initiative not only propels GoodRx’s momentum in weight loss solutions, but also broadens its portfolio in offering significant savings on brand-name medications, making obesity treatment more accessible and affordable for millions.

Ryan Portela on LinkedIn

Thanks to our great partners at Pharmaceutical Commerce Magazine for allowing me to share some of the very exciting things happening with LogiPharma US!!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs